Abstract
ABSTRACT This case study examines JD Bioscience (JDB), a South Korean pharmaceutical start-up, using the quick screen framework and its scorecard tool. The underlying rationale (the “why”) is to combat the decision-making complexities involved with new assets for licensing and acquisition within the life science industry by utilizing simple rules (the “how”) via the quick screen tool (the “what”). This article aims to explore simple rules and heuristic decision making in life science opportunities. JDB’s final score of 2.87 reflects unique attributes and developmental risks around the firm, its lead asset, and its management team. The analysis supports the application of a simple rules decision-making framework for entrepreneurs, investors, and executives. This framework identifies an opportunity’s maturation stage and roadblocks the venture needs to address. The findings shed light on JDB’s trajectory and underscore the significance of employing strategic decision-making tools in navigating the complexities of the life sciences landscape.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the International Council for Small Business
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
